

Alberto Zambon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1003439/publications.pdf>

Version: 2024-02-01

28
papers

2,545
citations

516710

16
h-index

552781

26
g-index

28
all docs

28
docs citations

28
times ranked

3973
citing authors

#	ARTICLE	IF	CITATIONS
1	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. <i>Journal of Internal Medicine</i> , 2021, 290, 116-128.	6.0	21
2	The burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 435-441.	3.0	6
3	Red Yeast Rice for Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2021, 77, 620-628.	2.8	41
4	Lipid Profile and Vascular Remodelling in Young Dyslipidemic Subjects Treated with Nutraceuticals Derived from Red Yeast Rice. <i>Cardiovascular Therapeutics</i> , 2021, 2021, 1-8.	2.5	2
5	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021, 325, 99-109.	0.8	83
6	Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial. <i>Diabetologia</i> , 2021, 64, 2334-2344.	6.3	9
7	The Association of Proprotein Convertase Subtilisin/Kexin Type 9 to Plasma Low-Density Lipoproteins: An Evaluation of Different Methods. <i>Metabolites</i> , 2021, 11, 861.	2.9	0
8	Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction. <i>Current Atherosclerosis Reports</i> , 2020, 22, 74.	4.8	9
9	Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1477-1489.	3.1	2
10	Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2020, 160, 105060.	7.1	30
11	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. <i>Atherosclerosis Supplements</i> , 2020, 42, e30-e34.	1.2	6
12	Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. <i>Nature Reviews Endocrinology</i> , 2020, 16, 177-189.	9.6	790
13	Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia. <i>Diabetes Mellitus</i> , 2020, 23, 65-71.	1.9	6
14	Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 715-725.	11.4	687
15	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM α) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	6.8	104
16	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016, 18, C2-C12.	0.1	71
17	SGLT2 Inhibitors and the Diabetic Kidney. <i>Diabetes Care</i> , 2016, 39, S165-S171.	8.6	279
18	The new ACC/AHA guidelines on the treatment of dyslipidemia: cons. <i>Internal and Emergency Medicine</i> , 2015, 10, 119-122.	2.0	1

#	ARTICLE	IF	CITATIONS
19	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate+statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015, 19, 1-12.	1.2	66
20	Effects of Niacin Combination Therapy With Statin or Bile Acid Resin on Lipoproteins and Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2014, 113, 1494-1498.	1.6	24
21	Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: A flag for non-HDL-C. <i>Atherosclerosis</i> , 2013, 230, 106-109.	0.8	26
22	Residual cardiovascular risk in secondary prevention. <i>Internal and Emergency Medicine</i> , 2011, 6, 61-68.	2.0	6
23	Common hepatic lipase gene promoter variant predicts the degree of neointima formation after carotid endarterectomy: Impact of plaque composition and lipoprotein phenotype. <i>Atherosclerosis</i> , 2006, 185, 121-126.	0.8	7
24	Review article: the metabolic syndrome - a chronic cardiovascular inflammatory condition. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 20-23.	3.7	48
25	The Multicentre Atorvastatin Plaque Stabilisation (MAPS) Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2003, 10, 11-18.	2.2	0
26	Hepatic lipase: a marker for cardiovascular disease risk and response to therapy. <i>Current Opinion in Lipidology</i> , 2003, 14, 179-189.	2.7	88
27	Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins. <i>Biochemical Society Transactions</i> , 2003, 31, 1070-1074.	3.4	62
28	Compositional Differences of LDL Particles in Normal Subjects With LDL Subclass Phenotype A and LDL Subclass Phenotype B. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 1040-1046.	2.4	71